281 related articles for article (PubMed ID: 35399125)
1. The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
Willison AG; Ruck T; Lenz G; Hartung HP; Meuth SG
J Neurol; 2022 Jul; 269(7):3937-3958. PubMed ID: 35399125
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
[TBL] [Abstract][Full Text] [Related]
3. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.
Abrahamsson SV; Angelini DF; Dubinsky AN; Morel E; Oh U; Jones JL; Carassiti D; Reynolds R; Salvetti M; Calabresi PA; Coles AJ; Battistini L; Martin R; Burt RK; Muraro PA
Brain; 2013 Sep; 136(Pt 9):2888-903. PubMed ID: 23864273
[TBL] [Abstract][Full Text] [Related]
4. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
[TBL] [Abstract][Full Text] [Related]
5. [Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation].
Willison AG; Meuth SG
Nervenarzt; 2022 Oct; 93(10):987-999. PubMed ID: 35951049
[TBL] [Abstract][Full Text] [Related]
6. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
7. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
8. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
[TBL] [Abstract][Full Text] [Related]
9. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
[TBL] [Abstract][Full Text] [Related]
10. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
12. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.
Ge F; Lin H; Li Z; Chang T
Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563
[TBL] [Abstract][Full Text] [Related]
14. Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances.
Mariottini A; De Matteis E; Cencioni MT; Muraro PA
Curr Neurol Neurosci Rep; 2023 Sep; 23(9):507-520. PubMed ID: 37589918
[TBL] [Abstract][Full Text] [Related]
15. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
[TBL] [Abstract][Full Text] [Related]
16. Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status.
Mariottini A; De Matteis E; Muraro PA
BioDrugs; 2020 Jun; 34(3):307-325. PubMed ID: 32166703
[TBL] [Abstract][Full Text] [Related]
17. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
[TBL] [Abstract][Full Text] [Related]
18. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
[TBL] [Abstract][Full Text] [Related]
19. Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.
Silfverberg T; Zjukovskaja C; Ljungman P; Nahimi A; Ahlstrand E; Dreimane A; Einarsdottir S; Fagius J; Iacobaeus E; Hägglund H; Lange N; Lenhoff S; Lycke J; Mellergård J; Piehl F; Svenningsson A; Tolf A; Cherif H; Carlson K; Burman J
J Neurol Neurosurg Psychiatry; 2024 Jan; 95(2):125-133. PubMed ID: 37748927
[TBL] [Abstract][Full Text] [Related]
20. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]